QPPV.COM KNOWLEDGE ASSESSMENT

Zanidatamab: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Zanidatamab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which clinical feature would most strongly support distinguishing a suspected zanidatamab infusion reaction from a delayed event?

Symptoms occurring in relation to infusion initiation or a rate increase A historical diagnosis of biliary tract cancer alone A stable baseline IHC result The fact that the patient previously received systemic therapy

Question 2 of 10 What is the principal pharmacovigilance value of documenting premedication and rescue medicines in an infusion-reaction case?

It demonstrates that the event cannot be related to zanidatamab It helps characterize prevention, management and the clinical severity of the reaction It replaces the need to document symptoms and vital signs It establishes that the patient had anaphylaxis

Question 3 of 10 What is the most appropriate interpretation of conditional authorisation for individual case processing?

Conditional authorisation removes the need to assess seriousness and expectedness Conditional authorisation changes the authorised indication but not the basic individual case-processing rules Conditional authorisation means all adverse events are automatically unexpected Conditional authorisation permits omission of biomarker and treatment-line information

Question 4 of 10 Which factor is least appropriate to ignore when evaluating a possible LVEF decline during zanidatamab treatment?

Prior anthracycline exposure Baseline cardiac disease Measurement variability The patient's preferred infusion-day meal

Question 5 of 10 Which patient most closely matches the EU-authorised population described in the article?

An adult with resectable breast cancer, HER2 IHC 3+, and no prior systemic therapy An adult with metastatic biliary tract cancer, HER2 IHC 3+, and at least one prior systemic therapy An adult with locally advanced biliary tract cancer, HER2 IHC 2+ with amplification, and no prior therapy An adolescent with metastatic biliary tract cancer, HER2 IHC 3+, and one prior local treatment

Question 6 of 10 Which statement correctly distinguishes seriousness from expectedness?

Seriousness depends on frequency, whereas expectedness depends on hospitalisation Seriousness concerns regulatory outcome criteria, whereas expectedness is assessed against current reference safety information A serious event is always unexpected An expected event cannot be serious

Question 7 of 10 A patient has an asymptomatic fall in LVEF on scheduled imaging. What is the most appropriate interpretation?

It should immediately be coded as symptomatic heart failure It is clinically irrelevant unless the patient reports dyspnoea It should be documented with baseline and follow-up values, method, timing and clinical interpretation It proves that zanidatamab caused the change

Question 8 of 10 A patient is hospitalised for dehydration caused by diarrhoea that is already a labelled adverse reaction. How should seriousness be assessed?

It is non-serious because diarrhoea is expected Hospitalisation can make the case serious even when the event itself is labelled It is serious only if the event is fatal Expectedness determines seriousness, so no separate assessment is needed

Question 9 of 10 Which statement best describes the relationship between HER2 biology and cardiac monitoring?

Cardiac monitoring is irrelevant because zanidatamab acts only on tumour tissue HER2 has physiologic cardiac roles, so left ventricular function should be followed according to product information Any reduction in LVEF proves symptomatic heart failure Cardiac monitoring is required only when an infusion reaction occurs

Question 10 of 10 Which statement best reflects the administration schedule described for zanidatamab?

It is administered intravenously every two weeks, with premedication used to reduce infusion-related reactions It is administered orally once daily without infusion monitoring It is administered subcutaneously only when diarrhoea occurs It is administered intravenously once per year without dose or rate documentation

QPPV.com

Zanidatamab: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings